TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04084210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Nicotine Cigarettes
Description: These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Nicotine Cigarettes
Description: These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).

Intervention type: DRUG
Group type: OTHER
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).

Intervention type: DRUG
Group type: OTHER
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.
Study: NCT00098774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
Study: NCT04084210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.
Study: NCT03448185

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga
Description: Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil capsules
Description: Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive oil capsules
Description: Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
Study: NCT02299557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline gel
Description: Oxymetazoline gel applied intra-anally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel applied intra-anally once daily
Study: NCT04227106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EB-101
Description: autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
Study: NCT01500707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900800
Description: SCH 900800, one 20 mg tablet, orally
Study: NCT01276093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI ablation
Description: Pulmonary Vein Ablation using RF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone tablets
Study: NCT04084210

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.
Study: NCT02617459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobetaxolol eye drops
Description: one drop per time; twice daily
Study: NCT04084210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.
Study: NCT03342807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin infusion for subjects in Group Insulin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aphesis
Description: Aphesis for subjects in Group Aphesis.
Study: NCT02505945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LINX Reflux Management System
Study: NCT02827773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talking Pill Bottle
Description: Made by Talking Rx
Study: NCT02218346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG221
Description: AG221 in fed and fasted conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG221
Description: AG221 in fed and fasted conditions
Study: NCT02539680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: duodenal biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: duodenal biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: duodenal biopsies
Study: NCT06030531

Intervention type: OTHER
Intervention: Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation
Description: We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
Study: NCT00098774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/sq m PO Days 7-11 Cycles 1-5.
Study: NCT02617459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaxolol eye drops
Description: one drop per time; twice daily
Study: NCT03204773

Intervention type: DIAGNOSTIC_TEST
Intervention: EuroQol five dimensions questionaire (EQ-5D)
Description: Testing quality of life.
Study: NCT02522130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intracervical injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral misoprostol
Description: oral treatment
Study: NCT02522130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: oral treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral treatment
Study: NCT03204773

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Fatigue Impact Scale (MFI)
Description: Screening for fatigue

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Fatigue Impact Scale (MFI)
Description: Screening for fatigue

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory (BPI)
Description: Testing for pain
Study: NCT04741763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EyePromise Visual Edge
Description: A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
Study: NCT03204773

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory (BPI)
Description: Testing for pain

Intervention type: DIAGNOSTIC_TEST
Intervention: Becks Depression Inventory (BDI)
Description: Screening for depression

Intervention type: DIAGNOSTIC_TEST
Intervention: Becks Depression Inventory (BDI)
Description: Screening for depression

Intervention type: DIAGNOSTIC_TEST
Intervention: Restless-leg Questionaire (RLS diagnostic criteria)
Description: Testing for restless-legs

Intervention type: DIAGNOSTIC_TEST
Intervention: Restless-leg Questionaire (RLS diagnostic criteria)
Description: Testing for restless-legs
Study: NCT01921985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
Study: NCT06030531

Intervention type: OTHER
Intervention: Analysis of biomarkers
Description: We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.

Intervention type: OTHER
Intervention: Analysis of biomarkers
Description: We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
Study: NCT04148976

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary portfolio
Description: A mixture of functional foods divided into 30g individual packets.
Study: NCT00547885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocodeine
Description: Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocodeine
Description: Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting
Study: NCT04151030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEG placement
Description: Push PEG placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEG placement
Description: Push PEG placement
Study: NCT03956771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real neurofeedback
Description: Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
Study: NCT04741763

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EyePromise Visual Edge
Description: A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
Study: NCT01153698

Intervention type: DRUG
Intervention: dabigatran
Description: anticoagulation
Study: NCT01513122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / ritonavir
Description: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / ritonavir
Description: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-3N(t)RTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg 1 tablet twice daily.
Study: NCT03218930

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed antibiotic prescription
Description: Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Antibiotic prescribing guidelines
Description: Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: General practitioners will receive a package of educational sessions tailored towards their specific needs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational materials
Description: Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
Study: NCT04583956

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Risankizumab placebo will be given at an equal volume at the same schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
Study: NCT04930263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: control group received routine care and a manual on healthy living
Study: NCT03236727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
Study: NCT01775878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring Device
Description: Telemonitoring device was installed in patients' homes
Study: NCT03674476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-986036
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986036
Description: Specified dose on specified days
Study: NCT04379310

Intervention type: DRUG
Intervention: ACE Inhibitors and Calcium Channel Blockers
Description: effect of drugs on patients with covid-19 pneumonia
Study: NCT03014024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser therapy
Description: This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
Study: NCT00065845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burch urethropexy at time of sacrocolpopexy
Description: The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
Study: NCT01143584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk.
Study: NCT04602247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC
Description: Sodium Iron Chlorophyllin, whose bioavailability is to be studied

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIC + AA combined
Description: Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
Study: NCT02961283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN003 ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN003 MTD
Description: The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
Study: NCT04602247

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4
Description: Ferrous sulfate serves as a positive control, whose iron bioavailability is known

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4 + AA combined
Description: Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EP + FeSO4 combined
Description: Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EP + FeSO4 + AA combined
Description: Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4
Study: NCT05564585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio tape was applied over the calf muscle of either leg.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: The sham tape was applied over the calf muscle of either leg.
Study: NCT06224803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Compound plant extracts
Description: Total supplement including bitter melon (Momordica charantia) fruit extract, celery (Apium graveolens) seed extract, baker's yeast (Saccharomyces cerevisiae) cell wall extract, acerola (Malpighia emarginata) fruit extract, grape (Vitis vinifera) seed extract, green tea leaf extract, and hydrolyzed soy protein powder.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Indigestible dextrin
Description: Indigestible dextrin as placebo intervention
Study: NCT03336164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling Nutri-Score
Description: Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
Study: NCT04434703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin (PRF)
Description: following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced platelet rich fibrin (A-PRF)
Description: following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: blood clot
Description: following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
Study: NCT00503321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)
Description: S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur/gimeracil/oteracil potassium (S-1)
Description: S-1 80mg/m2, 4weeks on followed by 2 weks off